DHRS9 and myeloid sarcoma: It is also worth noting that, even though DHRS9 could not be confirmed as a biomarker of vitD3-tolDC from MS patients, this does not mean that it could not still be useful in cells generated from patients with a different autoimmune disease, such as rheumatoid arthritis or type 1 diabetes.